Inhibition of angiogenesis
AssigneeTransmolecular, Inc.
InventorsDouglas B. Jacoby, Kamala Kesavan, Abdellah Sentissi, E. Michael Egan
Life of this patent
Estimating the term…
Abstract
The present invention is directed to novel methods of inhibiting angiogenesis using chlorotoxin agents. In some embodiments, the inventive methods include intravenous, intraocular, intravitreal, subjunctival injection, and/or topical administration of a chlorotoxin agent that may or may not be labeled. In some embodiments, the inventive methods allow treatment and/or amelioration of ocular diseases characterized by neovascularization, such as wet macular degeneration. In some embodiments, neovascularization is inhibited and/or newly formed vessels are caused to regress.
Claims51
A method comprising a step of administering an amount of chlorotoxin agent to a subject, wherein the amount of chlorotoxin is effective such that extent of angiogenesis is reduced as compared with that observed or expected for a control subject to whom chlorotoxin agent is not administered.
A method of identifying agents that bind competitively with chlorotoxin to Annexin A2, comprising
- a) providing a sample comprising cells that express Annexin A2;
- b) contacting the sample with a test agent;
- c) determining whether the test agent binds competitively with chlorotoxin to Annexin A2;
- and
- d) identifying, based on the determination, the test agent as an agent that binds competitively with chlorotoxin to Annexin A2.
A method of modulating Annexin A2 activity in a cell that expresses Annexin A2 comprising contacting the cell with an agent that modulates Annexin A2 such that Annexin A2 activity is altered.
Dependencies are inferred from the claim text.